



Michael D. Howell, PhD

Michael Howell is chief scientific officer and head of translational science at Zura Bio, founder of Mountaineer Biosciences, and cofounder of Galileo Biosystems.

Based in the San Diego, CA, USA area, Dr. Howell is an immunologist with more than 25 years of experience in government, academia, and biopharma/biotech.

He has led research and development teams dedicated to the discovery of novel therapies and the integration of novel biomarker approaches into clinical development. His efforts have led to the approval of multiple therapies including Opzelura (ruxolitinib), Jakafi (ruxolitinib), Adbry/Adtralza (tralokinumab), Tezpire (tezepelumab), Skyrizi (rizankizumab), and others. He has helped develop novel diagnostic approaches to patient treatment, and his work has led to more than 60 publications and numerous patents.

Dr. Howell received his PhD in immunology from West Virginia University School of Medicine and completed his postdoctoral training at National Jewish Health. He was a faculty member at National Jewish Health and held roles of increasing responsibility at Boehringer Ingelheim, Immune Tolerance Network, MedImmune/AstraZeneca, and the Incyte Corporation.